trigger
receptor
express
myeloid
cell
critic
involv
pathogenesi
rheumatoid
arthriti
ra
contrast
cytokin
blocker
therapeut
blockad
blunt
excess
inflamm
preserv
capac
microbi
control
howev
natur
ligand
mechan
signal
still
yet
well
understood
imped
develop
clinic
relev
inhibitor
aim
studi
evalu
antiarthrit
activ
novel
ligandindepend
inhibitori
nonapeptid
ration
design
use
signal
chain
homo
oligomer
school
model
cell
signal
free
bound
macrophagetarget
nanoparticl
mimic
human
highdens
lipoprotein
use
treat
collageninduc
arthriti
cia
also
test
peptid
sequenc
helic
major
hdl
protein
apolipoprotein
ai
abl
perform
three
function
assist
selfassembl
target
particl
macrophag
block
signal
show
control
peptid
amelior
cia
protect
bone
cartilag
damag
therapeut
effect
accompani
reduct
plasma
level
macrophag
colonystimul
factor
proinflammatori
cytokin
tumour
necrosi
factora
interleukin
il
incorpor
alon
part
peptid
hdl
significantli
increas
therapeut
efficaci
collect
find
suggest
inhibitori
school
sequenc
may
promis
altern
treatment
ra
keyword
trigger
receptor
express
myeloid
cell
macrophag
therapeut
peptid
signal
chain
homooligomer
model
cell
signal
target
deliveri
inflamm
collageninduc
arthriti
macrophag
central
pathogenesi
rheumatoid
arthriti
ra
autoimmun
diseas
affect
approxim
world
popul
abund
activ
macrophag
inflam
synovi
membran
significantli
correl
sever
ra
therapi
fail
reduc
number
synovi
sublin
macrophag
unlik
clinic
effect
major
target
relat
macrophag
develop
activ
growth
differenti
includ
tumour
necrosi
factora
tnfa
macrophag
colonystimul
factor
mcsf
mcsfdepend
cell
known
essenti
collageninduc
arthriti
cia
develop
target
deliveri
antirheumat
drug
macrophag
anoth
highli
desir
strategi
treatment
ra
would
strike
cell
mediat
amplifi
perman
tissu
destruct
also
spare
cell
affect
joint
damag
trigger
receptor
express
myeloid
cell
contribut
ra
highli
express
synovium
ra
patient
activ
enhanc
releas
tnfa
mcsf
blockad
significantli
amelior
cia
importantli
recent
studi
knockout
ko
mice
suggest
contrast
cytokin
blocker
therapeut
blockad
blunt
excess
inflamm
preserv
capac
microbi
control
human
be
lack
signal
partner
fig
problem
resolv
infect
togeth
implic
promis
target
develop
new
ration
ra
therapi
convent
inhibitor
solubl
decoy
receptor
antagonist
block
receptor
bind
ligand
fig
howev
despit
recent
evid
peptidoglycan
recognit
protein
may
potenti
act
ligand
actual
natur
ligand
mechan
signal
still
yet
well
understood
imped
develop
clinic
relev
inhibitor
recent
use
new
model
transmembran
signal
signal
chain
homooligomer
school
model
design
inhibitori
nonapeptid
employ
novel
ligandindepend
mechan
receptor
inhibit
fig
demonstr
attenu
specif
inflammatori
respons
amelior
sepsi
nonsmal
cell
lung
cancer
nsclc
anim
model
also
use
selfassembl
lipopeptid
complex
mimic
human
highdens
lipoprotein
hdl
target
deliveri
macrophag
fig
show
increas
therapeut
efficaci
vivo
present
studi
investig
therapeut
effect
free
hdlbound
cia
demonstr
control
peptid
suppress
releas
proinflammatori
cytokin
mcsf
decreas
inflamm
protect
bone
cartilag
destruct
cia
also
investig
interact
free
hdlbound
macrophag
vitro
show
coloc
cell
membran
reach
site
action
outsid
insid
cell
next
design
peptid
sequenc
helic
major
hdl
protein
apolipoprotein
apo
ai
respect
suggest
combin
sequenc
abl
perform
three
function
assist
selfassembl
hdl
target
hdl
macrophag
silenc
signal
pathway
demonstr
first
time
similar
lipopeptid
complex
amelior
cia
collect
find
suggest
inhibitori
school
sequenc
may
promis
altern
treatment
ra
sodium
cholat
cholesteryl
oleat
chemic
purchas
sigmaaldrich
compani
st
loui
mo
usa
dmpc
racglycerol
dmpg
popc
racglycerol
popg
lissamin
rhodamin
b
sulfonyl
rho
bpe
cholesterol
purchas
avanti
polar
lipid
alabast
al
usa
murin
macrophag
cell
line
obtain
american
type
cultur
collect
atcc
manassa
va
usa
oppos
current
approach
synthet
peptid
design
util
novel
model
immun
signal
school
model
employ
ligandindepend
mechan
action
block
transmembran
interact
signal
partner
peptid
use
either
free
particlebound
form
reach
site
action
outsid
insid
cell
rout
respect
c
synthet
hdl
contain
either
methioninesulfoxid
apolipoprotein
apo
ai
protein
major
hdl
protein
peptid
depict
red
uptaken
macrophag
therebi
deliv
incorpor
payload
cell
contrast
nativ
hdl
unmodifi
apo
ai
depict
blue
transport
excess
cholesterol
peripher
tissu
liver
normal
uptaken
macrophag
abbrevi
apo
apolipoprotein
dnax
activ
protein
kda
hdl
highdens
lipoprotein
il
interleukin
itam
immunoreceptor
tyrosinebas
activ
motif
mcsf
macrophag
colonystimul
factor
school
signal
chain
homooligomer
tnf
tumour
necrosi
factor
trigger
receptor
express
myeloid
cell
oxid
apo
ai
peptid
solubil
use
phosphat
ph
react
twofold
molar
excess
dylight
nhydroxysuccinimid
nh
ester
incub
hr
peptid
solubil
use
sodium
bicarbon
ph
dimethyl
sulfoxid
vv
react
molar
excess
dylight
nh
ester
incub
hr
reaction
quench
use
ethanolamin
reaction
mixtur
purifi
use
rphplc
discoid
hdl
dhdl
complex
contain
equimolar
mixtur
synthes
essenti
previous
describ
molar
ratio
correspond
popc
popg
apo
ai
sodium
cholat
contain
equimolar
mixtur
oxid
apo
ai
peptid
peptid
correspond
dmpc
dmpg
sodium
cholat
contain
equimolar
mixtur
oxid
peptid
subset
experi
apo
ai
dylight
spheric
hdl
shdl
complex
contain
equimolar
mixtur
synthes
use
sodium
cholat
dialysi
procedur
substanti
previous
describ
molar
ratio
correspond
popc
cholesterol
cholesteryl
oleat
apo
ai
sodium
cholat
contain
equimolar
mixtur
oxid
apo
ai
peptid
correspond
popc
cholesterol
cholesteryl
oleat
sodium
cholat
contain
equimolar
mixtur
oxid
peptid
subset
experi
apo
ai
dylight
obtain
hdl
formul
purifi
character
describ
previous
balbc
murin
macrophag
cell
grown
sixwel
tissu
cultur
plate
contain
glass
coverslip
reach
target
confluenc
approxim
cell
incub
h
rho
blabel
hdl
subset
experi
rho
blabel
hdl
contain
dylight
apo
ai
dylight
use
stain
perform
describ
prolong
gold
antifad
dapi
mount
medium
use
mount
coverslip
slide
photograph
use
olympu
fluoresc
microscop
confoc
imag
perform
leica
tc
ii
laser
scan
confoc
microscop
previous
report
anim
experi
perform
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
nih
unit
state
depart
agricultur
usda
anim
welfar
act
cfr
part
experiment
procedur
approv
institut
anim
care
use
committe
bolder
biopath
complianc
regul
prior
studi
initi
anim
welfar
assur
number
experi
perform
accord
approv
protocol
anim
studi
perform
bolder
biopath
boulder
co
usa
cia
induc
male
mice
immun
bovin
type
ii
collagen
previous
describ
briefli
mice
inject
intraderm
freund
complet
adjuv
contain
lg
bovin
type
ii
collagen
mgml
final
concentr
base
tail
day
day
day
mice
random
bodi
weight
treatment
group
enrol
day
mean
mous
weight
g
arthriti
onset
occur
day
start
day
mice
inject
intraperiton
ip
daili
consecut
day
mgkg
mgkg
mgkg
mgkg
dose
equival
mg
dose
equival
mg
pb
mice
weigh
studi
day
prior
necropsi
daili
clinic
score
given
scale
paw
day
use
previous
describ
criteria
day
mice
kill
necropsi
end
studi
fore
paw
hind
paw
knee
harvest
fix
neutral
buffer
formalin
day
decalcifi
formic
acid
day
standard
process
paraffin
embed
section
lm
cut
stain
toluidin
blue
blue
hind
paw
fore
paw
knee
embed
section
frontal
plane
six
joint
anim
process
histopatholog
evalu
joint
assess
use
scale
inflamm
pannu
format
cartilag
damag
bone
resorpt
periost
new
bone
format
previous
report
sum
histopatholog
score
sum
five
paramet
scale
also
determin
plasma
collect
day
cytokin
analys
quantibodi
mous
cytokin
array
kit
raybiotech
norcross
ga
usa
accord
manufactur
instruct
statist
analys
perform
graphpad
prism
softwar
graphpad
la
jolla
ca
usa
result
express
mean
ae
sem
statist
differ
analys
use
analysi
varianc
bonferroni
adjust
p
valu
less
consid
signific
access
number
uniprotkbswissprot
knowledgebas
http
www
uniprotorg
protein
sequenc
discuss
research
articl
follow
human
human
apo
ai
intracellular
uptak
macrophag
coloc
previous
report
oxid
apo
ai
peptid
significantli
enhanc
vitro
macrophag
uptak
studi
use
fluoresc
microscopi
rho
blabel
lipid
first
demonstr
punctuat
pattern
interact
macrophag
fig
close
mimic
physiolog
interact
nativ
hdl
hepatocyt
mediat
scaveng
receptor
bi
srbi
confirm
intracellular
uptak
versu
nonspecif
cell
surfac
bind
next
examin
interact
macrophag
contain
rho
blabel
lipid
dylight
oxid
apo
ai
peptid
interact
result
intracellular
deliveri
lipid
peptid
compon
fig
suggest
whole
particl
uptaken
cell
like
receptormedi
mechan
pronounc
coloc
lipid
apo
ai
peptid
fig
demonstr
timepoint
particl
remain
intact
uptak
other
degrad
releas
lipid
peptid
content
intracellular
space
data
illustr
figur
b
gener
use
similar
result
observ
data
shown
data
also
indic
use
equimolar
mixtur
oxid
peptid
enhanc
uptak
discoid
spheric
shape
macrophag
vitro
compar
unmodifi
counterpart
data
shown
togeth
find
suggest
oxid
apo
ai
epitop
respons
interact
macrophag
expos
type
hdl
particl
use
cell
receptor
tcr
school
peptid
known
tcr
core
peptid
coloc
tcr
cell
membran
recent
demonstr
anoth
tcr
school
peptid
peptid
deriv
sever
acut
respiratori
syndrom
coronaviru
fusion
peptid
sequenc
coloc
tcr
exhibit
predict
cellrel
therapeut
activ
cia
present
studi
show
selfinsert
cell
membran
coloc
fig
importantli
coloc
observ
incub
macrophag
either
free
data
shown
shdlbound
fig
indic
reach
intramembran
site
action
outsid
insid
cell
thu
use
hdlbase
platform
macrophagetarget
deliveri
result
intracellular
uptak
follow
releas
incorpor
selfinsert
cell
membran
insid
cell
fig
rout
suggest
oxid
assist
selfassembl
hdl
also
target
particl
macrophag
evalu
antiarthrit
activ
free
hdlbound
inhibitori
sequenc
design
use
concept
transmembran
signal
macrophagetarget
drug
deliveri
util
cia
mous
model
wide
studi
autoimmun
model
ra
administ
mgkg
control
peptid
significantli
suppress
arthriti
sever
compar
administr
vehicl
differ
group
start
day
continu
day
fig
day
mean
ae
sem
clinic
arthriti
score
mice
treat
much
lower
observ
mice
ae
versu
ae
p
antiarthrit
effect
compar
mgkg
dexamethason
dex
use
posit
control
data
shown
effect
dose
depend
therapeut
activ
observ
free
administ
mgkg
data
shown
test
whether
incorpor
macrophagetarget
hdl
increas
therapeut
efficaci
cia
administ
daili
mg
despit
decreas
administr
dose
observ
therapeut
effect
either
discoid
spheric
shape
compar
observ
free
fig
treatment
either
also
reduc
cia
sever
activ
compar
observ
free
higher
dose
fig
togeth
confoc
data
find
first
time
demonstr
one
peptid
sequenc
promot
selfassembl
hdl
target
particl
macrophag
provid
therapeut
efficaci
vivo
interestingli
contrast
vehicleor
mice
cia
administr
sequencecontain
formul
result
increas
bodi
weight
compar
observ
nonarthrit
na
mice
fig
summari
data
collect
indic
gener
strong
antiarthrit
effect
cia
therebi
provid
first
experiment
vivo
evid
previous
predict
immunomodulatori
activ
peptid
autoimmun
diseas
includ
ra
incorpor
inhibitori
sequenc
macrophagespecif
hdl
substanti
increas
therapeut
efficaci
probabl
target
deliveri
andor
prolong
circulatori
halflif
peptid
afford
strategi
determin
whether
treatment
mice
cia
use
free
hdlbound
inhibitori
sequenc
reduc
chronic
inflamm
synovi
tissu
pannu
format
cartilag
destruct
bone
eros
next
examin
histopatholog
six
joint
anim
includ
fore
paw
hind
paw
knee
fig
lesion
observ
nonarthrit
naiv
mice
arthrit
mice
treat
dex
mgkg
shown
vehicletr
arthrit
mice
histopatholog
chang
consist
seen
type
ii
cia
fig
microscop
alter
includ
infiltr
synovium
periarticular
tissu
neutrophil
mononuclear
inflammatori
cell
inflamm
margin
zone
pannu
bone
resorpt
cartilag
damag
proteoglycan
loss
chondrocyt
death
collagen
matrix
destruct
arthrit
mice
treat
mgkg
fig
free
mgkg
data
shown
histopatholog
paramet
differ
significantli
vehicletr
mice
contrast
sixjoint
mean
histopatholog
paramet
overal
significantli
reduc
mice
cia
treat
use
either
higher
dose
free
inhibitori
sequenc
incorpor
hdl
fig
line
clinic
observ
fig
mice
treat
free
mgkg
reduct
sum
score
compar
vehicletr
mice
observ
similar
observ
dextreat
mice
reduct
data
shown
compar
mice
mice
treat
dose
significantli
reduc
inflamm
reduct
pannu
format
cartilag
damag
bone
resorpt
periost
bone
format
sum
score
fig
similar
tendenc
observ
c
b
fig
interact
highdens
lipoprotein
hdl
macrophag
coloc
fluoresc
microscopi
reveal
punctuat
pattern
interact
spheric
hdl
macrophag
close
mimic
receptormedi
physiolog
interact
nativ
hdl
hepatocyt
cell
incub
h
contain
rhodamin
rho
blabel
peptid
red
scale
bar
lm
b
confoc
microscopi
demonstr
upon
interact
lipid
protein
compon
deliv
intracellularli
macrophag
cell
incub
h
contain
rho
blabel
lipid
red
dylight
apo
ai
peptid
green
cell
nuclei
stain
dapi
dye
blue
scale
bar
lm
c
coloc
cell
membran
cell
incub
h
contain
dylight
green
stain
alexa
antibodi
red
scale
bar
lm
reduct
histopatholog
score
observ
mice
treat
compar
vehicleor
mice
line
clinic
find
fig
vari
fig
depend
particl
shape
composit
figur
show
repres
photomicrograph
joint
arthrit
mice
treat
free
form
dose
mgkg
well
differ
observ
arthrit
mice
treat
vehicl
control
peptid
fig
fore
hind
paw
joint
moder
sever
inflamm
cartilag
damag
moder
pannu
bone
resorpt
well
mild
periost
bone
format
joint
ankl
knee
joint
mice
mark
inflamm
moder
cartilag
damag
pannu
format
bone
resorpt
periost
bone
format
fig
markedli
thicken
synovi
membran
capsul
observ
vehicleand
mice
result
pannu
format
inflammatori
cell
infiltr
chronic
inflamm
destroy
joint
line
includ
cartilag
nearbi
support
structur
bone
fig
format
pannu
probabl
result
overgrowth
synoviocyt
observ
accumul
inflammatori
cell
led
deform
cartilag
bone
find
agre
observ
clinic
score
contrast
fore
hind
paw
joint
mice
cia
treat
free
mgkg
minim
inflamm
minim
cartilag
damag
observ
fig
knee
ankl
joint
anim
lesion
minim
inflamm
mild
evid
synovi
membran
thicken
pannu
format
fall
within
normal
limit
compar
nonarthrit
naiv
mice
fig
similar
histopatholog
observ
mice
cia
treat
either
shdlbound
shdlbound
fig
thu
line
clinic
observ
histopatholog
find
demonstr
specif
protect
effect
inhibitori
sequenc
cartilag
bone
eros
cia
contribut
macrophagederiv
proinflammatori
cytokin
mcsf
cia
well
establish
activ
known
enhanc
releas
cytokin
elucid
molecular
mechan
underli
reduct
sever
cia
mice
treat
inhibitori
sequenc
next
analys
plasma
cytokin
level
day
start
treatment
day
around
diseas
peak
day
arthriti
swell
plateau
region
expect
day
signific
differ
cytokin
level
group
mice
cia
observ
fig
day
substanti
chang
cytokin
level
compar
day
observ
vehicletr
mice
fig
anim
treat
mgkg
mgkg
data
shown
contrast
arthrit
mice
treat
mgkg
well
treat
plasma
level
tnfa
mcsf
decreas
day
pronouncedli
day
fig
shown
illustr
purpos
thu
free
hdlbound
inhibitori
sequenc
effect
reduc
plasma
cytokin
tnfa
mcsf
dosedepend
manner
avail
new
biolog
therapi
target
cytokin
greatli
improv
manag
ra
howev
respons
patient
ra
cytokin
blocker
often
inadequ
exampl
patient
respond
tnf
blocker
use
cytokin
blocker
may
also
caus
deleteri
side
effect
seriou
infect
malign
septic
arthriti
mechanist
agent
bind
free
cytokin
consid
high
interindividu
variabl
cytokin
level
ra
patient
suggest
therapeut
respons
cytokin
blocker
well
risk
complic
depend
baselin
cytokin
level
inde
patient
ra
baselin
tnf
associ
clinic
respons
infliximab
tnf
blocker
higher
dose
necessari
patient
high
baselin
tnf
wherea
lower
dose
infliximab
suffici
low
baselin
tnf
tnf
blocker
increas
risk
malign
dosedepend
lead
critic
need
person
treatment
use
cytokin
blocker
well
substanti
effort
avoid
excess
immunosuppress
addit
cytokin
blocker
protect
cartilag
damag
effect
bone
eros
contribut
pathogenesi
ra
may
serv
promis
therapeut
target
ra
suppress
specif
inflammatori
respons
preserv
immun
system
abil
fight
infect
studi
appli
technolog
ligandindepend
inhibit
macrophagetarget
drug
deliveri
fig
cia
model
ra
predict
free
hdlbound
inhibitori
sequenc
employ
school
mechan
action
fig
first
time
shown
amelior
cia
protect
mice
cartilag
bone
damag
accord
school
model
control
peptid
lysin
replac
glycin
exhibit
therapeut
activ
cia
fig
suggest
specif
observ
therapeut
effect
mechanist
similar
school
peptid
free
selfinsert
plasma
membran
outsid
cell
disconnect
fig
rout
observ
coloc
membran
macrophag
incub
free
data
shown
confirm
mechan
line
find
report
school
peptid
togeth
intrigu
abil
differ
virus
use
school
mechan
disarm
tcr
receptor
involv
host
immun
respons
find
support
unifi
hypothesi
viral
immun
evas
strategi
develop
optim
million
year
fig
treatment
inhibitori
peptid
sequenc
reduc
plasma
cytokin
collageninduc
arthriti
plasma
collect
day
arthrit
mice
treat
vehicl
black
blue
spheric
hdl
red
shdl
contain
equimolar
mixtur
purpl
plasma
sampl
analys
concentr
tumour
necrosi
factora
tnfa
macrophag
colonystimul
factor
mcsf
result
express
mean
ae
sem
n
mice
per
group
p
p
versu
vehicl
consid
short
halflif
peptid
vivo
lack
cell
specif
selfinsert
process
use
reconstitut
synthet
hdlbase
deliveri
platform
provid
target
deliveri
macrophag
prolong
peptid
halflif
fig
expect
contrast
free
inact
mgkg
hdlbound
dose
therapeut
effect
treat
mice
cia
fig
although
underli
molecular
mechan
phenomenon
need
elucid
one
suggest
may
result
target
deliveri
inhibitori
sequenc
macrophag
andor
prolong
circulatori
halflif
hdlbound
peptid
confoc
data
fig
suggest
line
previou
data
methioninesulfoxid
apo
ai
epitop
involv
interact
hdl
macrophag
expos
type
hdl
particl
provid
intracellular
deliveri
inhibitori
sequenc
macrophag
probabl
receptormedi
manner
hand
vivo
peptid
halflif
typic
minut
nativ
dhdl
shdl
character
much
longer
halfliv
hour
day
respect
could
result
less
frequent
administr
turn
might
improv
complianc
confoc
data
vitro
fig
therapeut
efficaci
hdlbase
formul
observ
vivo
suggest
inhibitori
sequenc
intracellularli
deliv
macrophag
reach
site
action
membran
insid
cell
use
hdl
vehicl
system
deliveri
drug
increasingli
import
togeth
advanc
clinic
develop
reconstitut
hdl
per
se
drug
capabl
synthet
apo
ai
peptid
function
replac
human
apo
ai
demonstr
mice
cia
studi
well
mice
sepsi
atherosclerosi
lung
cancer
encourag
develop
hdlbase
deliveri
platform
knowledg
studi
first
demonstr
inhibitori
function
combin
one
sequenc
seemingli
unrel
function
peptid
result
multifunct
peptid
present
studi
trifunct
peptid
shown
assist
selfassembl
hdl
target
particl
macrophag
inhibit
suggest
multifunct
peptid
target
andor
receptor
express
macrophag
design
use
develop
nextgener
peptidebas
therapi
ra
diseas
molecular
level
activ
mediat
product
multipl
cytokin
growth
factor
involv
pathogenesi
ra
among
tnfa
serv
target
cytokineblock
therapi
current
develop
eg
differ
phase
clinic
trial
eg
mcsf
approv
eg
tnfa
blocker
present
studi
inhibitori
sequenc
significantli
reduc
plasma
level
proinflammatori
cytokin
mcsf
mice
cia
specif
dosedepend
manner
interestingli
mcsf
play
role
promot
tumour
growth
progress
metastasi
current
sever
inhibitor
mcsf
receptor
variou
stage
clinic
develop
cancer
therapi
thu
mcsf
may
repres
import
mechanist
link
antiarthrit
activ
inhibitori
sequenc
observ
studi
anticanc
activ
previous
observ
two
xenograft
model
nsclc
line
recent
studi
mcsf
suggest
underli
factor
facilit
tumour
progress
metastasi
arthrit
pyv
mt
mice
studi
need
confirm
hypothesi
summari
studi
provid
compel
vivo
evid
support
potent
therapeut
effect
inhibitori
sequenc
cia
expand
rang
applic
school
peptid
sequencebas
formul
oncolog
sepsi
autoimmun
diseas
rheumatoid
arthriti
system
lupu
erythematosu
coliti
inflammatori
bowel
diseas
blockad
clinic
import
togeth
previou
studi
work
also
suggest
potenti
theranost
applic
hdlbase
deliveri
platform
autoimmun
diseas
